Medicare AdvantageCoverageMedium impact
MA06.036, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA06.036 was reissued effective October 1, 2025, establishing updated coverage criteria for protein biomarkers used in prostate cancer diagnosis and risk assessment. The billing team must verify which specific biomarker tests are covered under this Medicare Advantage policy and ensure claims are submitted with appropriate documentation supporting medical necessity for cancer risk assessment or diagnosis.
Action Required
By October 1, 2025: Billing team must obtain and review the full text of policy MA06.036 from the source URL to identify: (1) which specific protein biomarker CPT/HCPCS codes are covered, (2) any prior authorization requirements, (3) medical necessity documentation requirements. Update billing system rules, prior authorization workflows, and provider encounter templates accordingly. Coordinate with urology providers to ensure proper documentation of cancer risk assessment or diagnostic indications on all claims. Failure to comply may result in claim denials or downcoding.